Cantor Fitzgerald Upgrades Mesoblast (NASDAQ:MESO) to “Strong-Buy”

Mesoblast (NASDAQ:MESO) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

MESO has been the subject of a number of other reports. Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Piper Sandler increased their price objective on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $13.50.

Mesoblast Price Performance

NASDAQ MESO opened at $20.14 on Thursday. The firm’s fifty day moving average price is $15.67 and its two-hundred day moving average price is $10.58. Mesoblast has a 1 year low of $1.75 and a 1 year high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Hedge Funds Weigh In On Mesoblast

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC raised its holdings in shares of Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after buying an additional 26,959 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Mesoblast in the second quarter worth about $562,000. Ballentine Partners LLC acquired a new stake in shares of Mesoblast in the 4th quarter valued at approximately $222,000. Signaturefd LLC grew its holdings in shares of Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after purchasing an additional 3,099 shares during the last quarter. Finally, Creative Planning acquired a new position in Mesoblast during the 3rd quarter worth approximately $147,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.